1093 Stock Overview
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, the Americas, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
CSPC Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.16 |
| 52 Week High | HK$9.56 |
| 52 Week Low | HK$5.20 |
| Beta | 0.88 |
| 1 Month Change | 4.99% |
| 3 Month Change | 21.36% |
| 1 Year Change | -21.23% |
| 3 Year Change | -8.21% |
| 5 Year Change | 3.99% |
| Change since IPO | 1,597.19% |
Recent News & Updates
Recent updates
Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?
Oct 22
Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price
Jul 09Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 01CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11
Apr 04CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price
Mar 12We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease
Dec 26CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 98% Above Its Share Price
Oct 18CSPC Pharmaceutical Group (HKG:1093) Could Easily Take On More Debt
Sep 15CSPC Pharmaceutical Group (HKG:1093) Will Pay A Larger Dividend Than Last Year At CN¥0.10
Aug 26CSPC Pharmaceutical Group (HKG:1093) Will Pay A Larger Dividend Than Last Year At HK$0.10
May 27CSPC Pharmaceutical Group (HKG:1093) Has Announced That It Will Be Increasing Its Dividend To HK$0.10
Apr 27CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To HK$0.10
Apr 04With EPS Growth And More, CSPC Pharmaceutical Group (HKG:1093) Is Interesting
Jan 12Here's Why I Think CSPC Pharmaceutical Group (HKG:1093) Is An Interesting Stock
Oct 04CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To HK$0.08
Aug 28CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 40% Below Their Intrinsic Value Estimate
Aug 06Do CSPC Pharmaceutical Group's (HKG:1093) Earnings Warrant Your Attention?
Jun 26Shareholder Returns
| 1093 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 3.0% | 1.2% | -3.0% |
| 1Y | -21.2% | -8.7% | -7.7% |
Return vs Industry: 1093 underperformed the Hong Kong Pharmaceuticals industry which returned -7.9% over the past year.
Return vs Market: 1093 underperformed the Hong Kong Market which returned -7.3% over the past year.
Price Volatility
| 1093 volatility | |
|---|---|
| 1093 Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 14.5% |
| 10% least volatile stocks in HK Market | 3.2% |
Stable Share Price: 1093 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 1093's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 25,587 | Cuilong Zhang | https://www.cspc.com.hk |
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer.
CSPC Pharmaceutical Group Limited Fundamentals Summary
| 1093 fundamental statistics | |
|---|---|
| Market Cap | HK$84.84b |
| Earnings (TTM) | HK$6.69b |
| Revenue (TTM) | HK$34.26b |
12.7x
P/E Ratio2.5x
P/S RatioIs 1093 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1093 income statement (TTM) | |
|---|---|
| Revenue | CN¥31.31b |
| Cost of Revenue | CN¥9.34b |
| Gross Profit | CN¥21.97b |
| Other Expenses | CN¥15.85b |
| Earnings | CN¥6.12b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.52 |
| Gross Margin | 70.17% |
| Net Profit Margin | 19.54% |
| Debt/Equity Ratio | 0.2% |
How did 1093 perform over the long term?
See historical performance and comparison